The short version of trans-3-hexenoyl fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Molten salt baths belong to the oldest thermal cleaning systems; cleaning with a molten salt bath is very fast but implies the risk of dangerous splatters, or other potential hazards connected with the use of salt baths, like explosions or highly toxic hydrogen cyanide gas. Fluidized bed systems use sand or aluminium oxide as heating medium; these systems also clean very fast but the medium does not melt or boil, nor emit any vapors or odors; the cleaning process takes one to two hours. Vacuum ovens use pyrolysis in a vacuum avoiding uncontrolled combustion inside the cleaning chamber; the cleaning process takes 8 to 30 hours. Burn-off ovens, also known as heat-cleaning ovens, are gas-fired and used in the painting, coatings, electric motors and plastics industries for removing organics from heavy and large metal parts.
=== ENOUGH === Funded by: Horizon 2020 (European Commission) and European Green Deal Duration: 4 years (October 2021-September 2025) Objective: The main scope of the project is to support the EU farm-to-fork sustainable strategy by providing technical, financial, and political tools and solutions to reduce GHG emissions (by 2030) and achieve carbon neutrality (by 2050) in the food industry.
Promession is a disposal technique for human remains involving freeze drying. It was first proposed in Sweden as an alternative to cremation. It was marketed as being more environmentally friendly than other methods of disposal, as it avoided the potential pollution of groundwater, which can occur with the use of traditional burial. It was also marketed as a way of saving space. However, it has never been carried out on a human being, and is not currently commercially available. Promession has been suggested as a means to deal with the corpse a from human death in space.
Sources: en.wikipedia.org
=== Mayor of San Salvador === In August 2014, Bukele announced that he would seek election as mayor of San Salvador in the 2015 elections. His candidacy was confirmed by FMLN secretary-general Medardo González on 19 August 2014. Bukele delegated administration of Nuevo Cuscatlán to council member Michelle Sol in February 2015 to focus on his campaign. During his campaign, which was supported by the Salvadoran Progressive Party, FMLN party leadership called Bukele the party's "crown jewel" ("joya de la corona"). Bukele's campaign used catchphrases such as "we have to change history" ("tenemos que cambiar la historia") and "together we will go forward" ("juntos saldremos adelante") to rally support from young voters. His primary opponent was Edwin Zamora, a businessman and Legislative Assembly deputy from ARENA. Bukele led Zamora in opinion polls before the election. He defeated Zamora with 50.38 percent of the vote on 1 March 2015, and took office on 1 May. Bukele appointed a cousin, Hassan, and his half-brother Yamil to administrative positions on the San Salvador municipal council. The appointments were criticized by ARENA and FMLN politicians.
=== Judith Mossman === Dr. Judith Mossman (voiced by Michelle Forbes) is introduced in Half-Life 2 as a physicist working with Eli Vance at the Black Mesa East Research Facility. Although she is apparently friendly with other scientists, her condescending attitude toward laypeople annoys Alyx. Over the course of the game, she is revealed as a triple agent who betrays the resistance in an attempt to form an alliance with Dr. Breen, then betrays him in turn. In the follow-on episodes, she is again working for the resistance in a remote location. According to writer Marc Laidlaw, Judith Mossman was based on the character Elena Hausmann from his novel The Third Force: A Novel of Gadget (1996), based on the computer game Gadget: Invention, Travel, & Adventure (1993). He originally named the character Elena Mossman, but because it sounded too similar to the Gadget character, he renamed her to Judith Mossman.
The analysis done based on satellite measurement data, estimates δD for the air in various parts of the world. The general trend is that δD is more negative at higher latitude, so air above Antarctica and the Arctic is D-depleted to around −230‰ to −260‰ or even lower. The estimated atmospheric δDs are shown on the map. A vast portion of global atmospheric water vapor comes from the Western Pacific near the tropics, (mean 2009) and the HIC of air depends on temperature and humidity. Hot, humid regions generally have higher δD. Water vapor in the air is in general more depleted than terrestrial water sources, since 1H216O evaporates faster than 1H2H16O due to higher vapor pressure. On the other hand, rain water is in general more enriched than atmospheric water vapor.
There are two general classes of glutamate transporters, those that are dependent on an electrochemical gradient of sodium ions (the EAATs) and those that are not (VGLUTs and xCT). The cystine-glutamate antiporter (xCT) is localised to the plasma membrane of cells whilst vesicular glutamate transporters (VGLUTs) are found in the membrane of glutamate-containing synaptic vesicles. Na+-dependent EAATs are also dependent on transmembrane K+ and H+concentration gradients, and so are also known as 'sodium and potassium coupled glutamate transporters'. Na+-dependent transporters have also been called 'high-affinity glutamate transporters', though their glutamate affinity actually varies widely. EAATs are antiporters which carry one molecule of glutamate in along with three Na+ and one H+, while export one K+. EAATs are transmembrane integral proteins which traverse the plasmalemma 8 times. Mitochondria also possess mechanisms for taking up glutamate that are quite distinct from membrane glutamate transporters.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.